Shanghai Zhongshan Hospital
Clinical trials sponsored by Shanghai Zhongshan Hospital, explained in plain language.
-
Experimental CAR-T therapy takes on Hard-to-Treat liver cancer
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called IL1RAP-targeting CAR-T cells in just 3 people with advanced liver cancer that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Resea…
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a common vitamin tame a rare gut disease?
Disease control ENROLLING_BY_INVITATIONThis study tests whether taking vitamin B1 tablets for a year can reduce the size and number of colon polyps in people with familial adenomatous polyposis (FAP), a genetic condition that raises colon cancer risk. Ten adults with FAP who still have their colon will take vitamin B1…
Phase: NA • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could your own cells replace insulin shots? early trial aims to find out
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests whether insulin-making cells grown from a patient's own pancreatic tissue can be safely transplanted under the belly skin to reduce or replace insulin shots. Twenty-four adults with insulin-dependent type 2 diabetes will take part. The main goal is sa…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 part…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Double antibody attack: new hope for tough pancreatic cancer?
Disease control OngoingThis phase 2 trial tests whether adding a new antibody called HLX22 to standard treatment (trastuzumab plus chemotherapy) can shrink tumors and improve survival in people with HER2-positive pancreatic cancer that has spread. The study enrolls 45 adults who have not had prior trea…
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug cocktail aims to stop bile duct cancer from returning after surgery
Disease control OngoingThis study tests whether giving a combination of an immunotherapy drug (toripalimab), a targeted therapy (lenvatinib), and chemotherapy (GEMOX) before surgery can improve outcomes for people with a high-risk type of bile duct cancer. The trial includes 178 patients whose cancer i…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:52 UTC
-
AI reads scans to spot esophageal cancer and predicts best treatment path
Diagnosis OngoingThis study tests two AI models that analyze endoscopy and CT images to diagnose esophageal cancer and predict how deep the tumor has grown. The goal is to help doctors decide if a patient can be treated with a less invasive endoscopic procedure or needs more aggressive therapy. T…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
2,000 heart attack patients enrolled in landmark Data-Gathering study
Knowledge-focused OngoingThis study is observing 2,000 people who have had a heart attack to collect detailed medical information, images, and blood samples. Researchers will use this data to better understand different types of heart attacks and find new ways to predict and prevent future heart problems…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC